Get the Stockscreener App
9.94
1.84%
0.18
After Hours:
9.85
-0.09
-0.91%
Neumora Therapeutics Inc stock is traded at $9.94, with a volume of 435.73K.
It is up +1.84% in the last 24 hours and down -15.26% over the past month.
Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the global brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has rapidly scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. The company expects to continue to progress in the development of its pipeline with the planned initiation of multiple clinical trials across its programs over the next 12 to 18 months, which supports numerous anticipated data readouts.
See More
Previous Close:
$9.76
Open:
$9.84
24h Volume:
435.73K
Relative Volume:
0.42
Market Cap:
$1.61B
Revenue:
-
Net Income/Loss:
$-274.18M
P/E Ratio:
-5.7851
EPS:
-1.7182
Net Cash Flow:
$-198.33M
1W Performance:
+2.05%
1M Performance:
-15.26%
6M Performance:
+4.52%
1Y Performance:
-18.05%
1-Day Range:
$9.695
$10.13
1-Week Range:
$9.58
$10.13
52-Week Range:
$8.33
$21.00
Neumora Therapeutics Inc Stock (NMRA) Company Profile
Name
Neumora Therapeutics Inc
Sector
Industry
Phone
(857) 760-0900
Address
490 ARSENAL WAY, SUITE 200, WATERTOWN
Compare NMRA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NMRA
Neumora Therapeutics Inc
|
9.94 | 1.61B | 0 | -274.18M | -198.33M | -2.5346 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.13 | 120.56B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
750.22 | 82.44B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
616.55 | 36.87B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
253.07 | 32.64B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
118.39 | 28.38B | 3.30B | -501.07M | 1.03B | -2.1146 |
Neumora Therapeutics Inc Stock (NMRA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-05-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Oct-01-24 | Initiated | H.C. Wainwright | Buy |
| Jul-22-24 | Initiated | Needham | Buy |
| Jul-08-24 | Initiated | Mizuho | Outperform |
| Dec-12-23 | Initiated | Deutsche Bank | Hold |
| Oct-10-23 | Initiated | BofA Securities | Buy |
| Oct-10-23 | Initiated | Guggenheim | Buy |
| Oct-10-23 | Initiated | JP Morgan | Overweight |
| Oct-10-23 | Initiated | RBC Capital Mkts | Outperform |
| Oct-10-23 | Initiated | Stifel | Buy |
| Oct-10-23 | Initiated | William Blair | Outperform |
View All
Neumora Therapeutics Inc Stock (NMRA) Latest News
Head-To-Head Analysis: Neumora Therapeutics (NMRA) vs. Its Competitors - Defense World
Neumora Therapeutics' SWOT analysis: stock poised for growth amid MDD trial - Investing.com Canada
Neumora Therapeutics’ (NMRA) Outperform Rating Reiterated at Royal Bank of Canada - Defense World
Neumora Therapeutics' (NMRA) Outperform Rating Reiterated at Royal Bank of Canada - MarketBeat
Contrasting Neumora Therapeutics (NMRA) and Its Competitors - Defense World
Head-To-Head Survey: Neumora Therapeutics (NMRA) vs. Its Rivals - Defense World
Neumora Therapeutics, Inc. (NMRA): This Small-Cap Stock Is Ready To Explode - MSN
This biotech’s stock could double if its treatment for major depressive disorder succeeds, says Mizuho - MSN
10 Best Small-Cap Stocks Ready To Explode - Insider Monkey
Financial Comparison: Neumora Therapeutics (NMRA) and Its Rivals - Defense World
HC Wainwright Issues Pessimistic Forecast for NMRA Earnings - Defense World
Analysts Set Neumora Therapeutics, Inc. (NASDAQ:NMRA) Target Price at $21.67 - Defense World
Equities Analysts Set Expectations for NMRA FY2024 Earnings - Defense World
FY2024 Earnings Forecast for NMRA Issued By William Blair - MarketBeat
HC Wainwright Analysts Lower Earnings Estimates for NMRA - MarketBeat
This biotech’s stock may double on treatment for depression, says Mizuho - MarketWatch
SoftBank Group Corp.'s Strategic Reduction in Neumora Therapeuti - GuruFocus.com
Neumora Therapeutics (NASDAQ:NMRA) Announces Earnings Results, Misses Estimates By $0.06 EPS - MarketBeat
Needham & Company LLC Reiterates Buy Rating for Neumora Therapeutics (NASDAQ:NMRA) - MarketBeat
Neumora Therapeutics, Inc. (NASDAQ:NMRA) Receives $21.67 Average PT from Analysts - MarketBeat
Neumora Therapeutics Reports Q3 2024 Financial Results - TipRanks
Neumora Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Neumora Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update - The Manila Times
Neumora Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update - GlobeNewswire Inc.
Where Do Analysts Think The Neumora Therapeutics Inc (NASDAQ: NMRA) Is Going - Stocks Register
Neumora Therapeutics (NMRA) to Release Quarterly Earnings on Tuesday - Defense World
Objective long/short (NMRA) Report - Stock Traders Daily
Neumora Therapeutics downgraded to Neutral from Overweight at JPMorgan - MSN
What You Didn’t Know About Neumora Therapeutics Inc (NASDAQ: NMRA) This Week - Stocks Register
Neumora Therapeutics to Participate in Upcoming Conferences in November - The Manila Times
Neumora Therapeutics (NASDAQ:NMRA) Shares Gap DownHere's Why - MarketBeat
Neumora Therapeutics (NMRA) Set to Announce Quarterly Earnings on Tuesday - MarketBeat
Auour Investments LLC Takes $3.30 Million Position in Neumora Therapeutics, Inc. (NASDAQ:NMRA) - MarketBeat
This Cognex Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For TuesdayCognex (NASDAQ:CGNX) - Benzinga
Neumora Therapeutics (NASDAQ:NMRA) Downgraded by JPMorgan Chase & Co. to Neutral - MarketBeat
JPMorgan downgrades Neumora stock, warns of potential downside without data clarity - Investing.com UK
Critical Analysis: Neumora Therapeutics (NMRA) and The Competition - Defense World
Neumora Therapeutics to Report Third Quarter 2024 Financial Results on Tuesday, November 12, 2024 - The Manila Times
(NMRA) On The My Stocks Page - Stock Traders Daily
Neumora Therapeutics (NASDAQ:NMRA) Trading Down 4.5%Time to Sell? - MarketBeat
Neumora Therapeutics (NASDAQ:NMRA) Sees Large Volume IncreaseTime to Buy? - MarketBeat
Neumora Therapeutics (NASDAQ:NMRA) Shares Gap Down Following Insider Selling - Defense World
SG Americas Securities LLC Lowers Holdings in Neumora Therapeutics, Inc. (NASDAQ:NMRA) - Defense World
Bleakley Financial Group LLC Sells 1,966 Shares of Vanguard Mid-Cap Growth ETF (NYSEARCA:VOT) - Defense World
Neumora Therapeutics, Inc. (NASDAQ:NMRA) Shares Sold by SG Americas Securities LLC - MarketBeat
Neumora Therapeutics, Inc. (NASDAQ:NMRA) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Neumora Therapeutics, Inc. (NASDAQ:NMRA) Director Sells $239,254.47 in Stock - MarketBeat
Neumora Therapeutics director Matthew Fust sells $370,961 in stock - Investing.com India
Neumora Therapeutics director Matthew Fust sells $370,961 in stock By Investing.com - Investing.com South Africa
Neumora Therapeutics Inc Stock (NMRA) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.61%
1.14%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):